Could cannabis compounds curb opioid relapse? new study investigates
NCT ID NCT07148206
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 21 times
Summary
This study tests whether two FDA-approved cannabis-based drugs, dronabinol and epidiolex, can help people with opioid use disorder who have just started buprenorphine treatment. The goal is to see if these drugs can reduce withdrawal symptoms and opioid use, helping patients stay in treatment longer. About 40 participants will be enrolled early in their treatment journey.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Health System (Montefiore) Buprenorphine Treatment Network
The Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.